Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POEM Study
2024-519386-21-01Phase 3Authorised
- Sponsor
- Bethesda Diabetes Research Center
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of metformin in gestational diabetes mellitus (GDM) (2 arms), sponsored by Bethesda Diabetes Research Center. Primary endpoints: GDM Outcome Score (GOS) per pregnancy, Maternal type 2 diabetes mellitus and 2 more. Planned start Jan 2025; status: authorised.
02
Drugs
metformin
03
Conditions
gestational diabetes mellitus (GDM)
Beyond the preview
Go deeper on 2024-519386-21-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519386-21-01.